Developing therapeutics for diseases with impaired kidney function

ENYO Pharma is a clinical-stage biopharmaceutical company.

Our mission is to develop highly differentiated therapeutics for improving the quality of life of patients with impaired kidney function.

Our lead clinical compound VONAFEXOR is a small molecule with strong fibrolytic and anti-inflammatory properties in both organs, kidney and liver.
It is currently in Phase 2 development for rare kidney disease Alport Syndrome and Chronic Kidney Diseases (CKD).